Viewing nowCombinationLovatitan Tablets 5/80 mg
Valsartan 80mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.

MFDS item code 201404745 · Approved 2014.10.16 · Insurance code 668902880
Treatment of hypertension and heart failure, improvement of hyperlipidemia, and reduction of the risk of atherosclerosis, cardiovascular disease, and death
This medication is used for patients who require the simultaneous administration of valsartan and rosuvastatin. Valsartan is effective for essential hypertension, heart failure intolerant to ACE inhibitors, and for reducing the risk of death after myocardial infarction. Rosuvastatin helps control hypercholesterolemia, familial hypercholesterolemia, and various dyslipidemias, and is also used to reduce the risk of cardiovascular diseases and slow the progression of atherosclerosis. Together, these two medications play a critical role in improving cardiovascular health and reducing risk.
This medicine is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the valsartan and rosuvastatin components. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time every day (e.g., in the morning). 1) Adults: Regardless of sex or race, an oral dose of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. In patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be administered concomitantly. If additional blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance below 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., those taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administering concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy of this medicine with an ACE inhibitor and a beta blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended initial dose is 20 mg of this medicine twice daily, followed over several weeks by dose increases, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance below 10 mL/min or patients on dialysis, as there is no experience of use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which is adequate for most patients. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or longer, based on LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased up to a maximum of 20 milligrams daily. 2. Older adults: No dose adjustment is required. 3. Patients with renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience of use in patients with a Child-Pugh score above 9. Do not administer this medicine to patients with active liver disease. 5. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause severe harm to the fetus when taken during pregnancy, especially in the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. Women of childbearing potential should use appropriate contraception, and it is safe not to administer it to pregnant or breastfeeding women. Patients with severely impaired liver or kidney function, certain hereditary diseases, or muscular diseases should not use this medication. Elderly patients or those with hyperkalemia, liver disorders, etc., should use this medication with caution, and may require regular liver enzyme tests or kidney function tests as necessary. If muscle pain, weakness, or cramps occur, contact your doctor immediately, and discontinue the medication if muscle damage is severe. This medication may interact with other drugs, so notify your healthcare provider if you are taking other medications. There is no specific antidote in case of overdose; immediate medical attention is needed at a medical facility. Keep out of reach of children and do not transfer to another container. Be cautious of dizziness symptoms when driving or operating machinery.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, weakness, chest pain, facial edema, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferases, increased serum creatine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, decreased sensation, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fracture, spinal fracture, fracture, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, unspecified skin tumor-like condition, herpes zoster, intervertebral disc herniation, hemoptysis, sputum diseases, bronchitis, sensory disturbances, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, elevated blood pressure, hypertension exacerbation, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, unspecified dermatitis, localized skin reaction, palpitations, angina exacerbation, auditory disturbances, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, anemia, tinnitus, hypertonia, decreased motor function, confusion, rash, myalgia, vascular edema, hypersensitivity reaction, diabetes, headache, dizziness, constipation, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, peripheral neuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, liver failure, cognitive impairment, severe muscle weakness, ocular muscle weakness, hypotension, orthostatic dizziness, orthostatic hypotension, fatigue, renal dysfunction, hyperkalemia, angioedema, syncope, loss of consciousness, shock, hypotension, serum sickness, vasculitis, interstitial pneumonia, hypoglycemia, vascular edema, hepatitis, renal failure, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, decreased hematocrit, decreased hemoglobin, edema, weakness, insomnia, erythema, decreased libido, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, pharyngitis, arthralgia, drowsiness, atrial fibrillation, thirst, anorexia, malaise, vasculitis, epistaxis, hepatitis, arrhythmia, intestinal vascular edema, interstitial lung disease, rhabdomyolysis, immune-mediated necrotizing myopathy, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, severe muscle weakness, ocular muscle weakness
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to light, so it should be stored in a protective container that blocks light. Additionally, it is best to store the medication at room temperature between 1°C and 30°C. Proper storage ensures the medication maintains its effectiveness over time.
Bright orange round film-coated tablet
56 tablets (14 tablets/PTP x 4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationValsartan 80mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chemical Co., Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 20.8mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 80mg · Rosuvastatin Calcium Micronized 10.4mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
CombinationValsartan 160mg · Rosuvastatin Calcium Micronized 5.2mg
Tablet · Prescription medication · Combination
LG Chem, Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.